Cancer and Immunotherapy · global
Selectively Activating T Cells to Fight Cancer: Early Trial of New Immunotherapy Shows Tumor Shrinkage
When advanced cancers stop responding to existing immunotherapies, precisely activating a subset of T cells may offer another path. Invikafusp alfa showed preliminary efficacy in a small trial, but more complete evidence is needed to determine how long the effects last and which patients are most likely to benefit.
For patients with advanced cancer who have undergone multiple rounds of treatment, options often become increasingly limited after immunotherapy fails. An early clinical study published on October 23 in *Nature Medicine* provides preliminary evidence for another way to activate the immune system: the experimental drug invikafusp alfa caused tumors to shrink or temporarily remain stable in some patients with refractory solid tumors.
The drug, also known as invika, is a bispecific antibody that selectively activates T cells. It targets two groups of T cells bearing Vβ6 and Vβ10; according to Canada's University Health Network (UHN), these cells account for approximately one-tenth of all T cells and are also commonly found within tumors. The study's premise is to focus stimulation on these cells to promote an anticancer response while reducing the potential side effects of broadly activating immune cells. The trial did observe selective increases in the targeted cells in both blood and tumors.
The phase I/II trial, called START-001, was designed first to address safety and dosing questions. According to UHN's announcement, the study treated a total of 58 people at 10 cancer centers across four countries, with the primary analysis including 52 people across 21 types of solid tumors. Using a data cutoff of March 12, 2025, the paper reported results from 34 phase I participants and 18 early phase II participants. The total number treated cited in the announcement should therefore not be used directly as the denominator for the various efficacy figures.
Among 27 people who received 0.08 or 0.12 milligrams per kilogram of body weight, doses the research team defined as optimal biological doses, 4 achieved an objective response, a rate of 14.8%, meaning their tumor shrinkage met established assessment criteria. UHN also reported that 44.4% of this group experienced some degree of tumor shrinkage. The two figures measure different thresholds, so not all shrinkage can be considered a clinical response.
Patients whose previous immunotherapy had failed also showed a signal warranting further investigation: among 18 such patients in the dose groups described above, 66.7% achieved disease control, meaning their tumors shrank or remained stable. Responses documented in the paper included microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer. However, stable disease does not mean the cancer has disappeared, nor can these findings yet support an inference of longer survival.
Regarding safety, the most common treatment-related adverse event was cytokine release syndrome, mostly grade 1 or 2. The study recorded two cases of reversible dose-limiting toxicity and reported no treatment-related deaths. No objective responses were observed at doses below 0.08 milligrams per kilogram. After considering safety, the drug's behavior in the body, immune activity, and other data, the team selected 0.08 milligrams per kilogram as the recommended phase II dose.
These results support further research but are not yet sufficient to establish efficacy. The number of participants was small, their cancer types and treatment histories varied, and there is currently no control group for direct comparison. Increases in the targeted T cells were not always accompanied by tumor shrinkage. Larger studies and longer follow-up will be needed to clarify how long responses last, which patients are suitable, and whether the treatment offers meaningful benefits compared with existing therapies.
The trial was sponsored and funded by the drug's developer, Marengo Therapeutics, and the phase II study is ongoing. UHN also disclosed that co-senior author Lillian Siu serves as a scientific adviser to the company and holds equity in it. The clearest advances from this study so far are the identification of a dose for further testing and evidence in humans of selective T-cell activation and preliminary antitumor activity.